Versius

Stryker has agreed to invest roughly $400m in UK-based CMR Surgical and secured exclusive US sales rights for its Versius surgical robot, strengthening its challenge to Intuitive Surgical's dominant da Vinci system. Versius' modular design, using separate robotic arm carts that teams can arrange around the operating table, is seen as a key differentiator as the two companies compete in soft-tissue robotic surgery.

Medical device giant Stryker has invested $400 million in CMR Surgical, the UK-based maker of the Versius surgical robot. The deal signals Stryker's growing interest in soft-tissue robotics, one of the fastest-moving corners of medtech. The move comes as hospital demand for robotic surgery systems accelerates and competitors race to expand their robotic portfolios.

Medical device maker Stryker has agreed to pay $400 million for CMR Surgical's Versius soft-tissue robotic surgery system, moving the company deeper into surgical robotics. The deal hands Stryker a flexible robotic platform used in minimally invasive procedures, and industry watchers see it as a challenge to Intuitive Surgical's dominance in soft-tissue robotics and part of a broader consolidation wave among surgical robotics makers.